NR3C2 and Hyperkalemia: Remarkably, those patients randomized to dapagliflozin had half the incidence of moderate/severe hyperkalemia associated with mineralocorticoid receptor antagonists use, compared to placebo (1.4% vs. 2.4%; HR 0.50; 95% CI 0.29–0.85).